A *Mycobacterium leprae* Hsp65 Mutant as a Candidate for Mitigating Lupus Aggravation in Mice

Eliana B. Marengo¹, Luciana V. de Moraes², Robson L. Melo³, Andrea Balan⁴, Beatriz L. Fernandes³, Denise V. Tambourgi⁵, Luiz Vicente Rizzo¹, Osvaldo Augusto Sant’Anna⁵⁺

¹Hospital Israelita Albert Einstein, São Paulo, Brazil; ²Laboratório de Doenças Genéticas, Instituto Gulbenkian de Ciência, Oeiras, Portugal; ³Centro de Toxínologia Aplicada-CAT/CEPID, Instituto Butantan, São Paulo, Brazil; ⁴Laboratório Nacional de Biociências LNBlf, Centro de Pesquisa em Energia e Materiais, Polo II de Alta Tecnologia, Campinas, Brazil; ⁵Laboratório de Imunoquímica, Instituto Butantan, São Paulo, Brazil

**Abstract**

Hsp60 is an abundant and highly conserved family of intracellular molecules. Increased levels of this family of proteins have been observed in the extracellular compartment in chronic inflammation. Administration of *M. leprae* Hsp65 [WT] in [NZBxNZW]F1 mice accelerates the Systemic Lupus Erythematosus [SLE] progression whereas the point mutated K409A Hsp65 protein delays the disease. Here, the biological effects of *M. leprae* Hsp65 Leader pep and K409A pep synthetic peptides, which cover residues 352–371, are presented. Peptides had immunomodulatory effects similar to that observed with their respective proteins on survival and the combined administration of K409A+Leader pep or K409A pep+WT showed that the mutant forms were able to inhibit the deleterious effect of WT on mortality, indicating the neutralizing potential of the mutant molecules in SLE progression. Molecular modeling showed that replacing Lysine by Alanine affects the electrostatic potential of the 352–371 region. The number of interactions observed for WT is much higher than for Hsp65 K409A and mouse Hsp60. The immunomodulatory effects of the point-mutated protein and peptide occurred regardless of the catalytic activity. These findings may be related to the lack of effect on survival when F1 mice were inoculated with Hsp60 or K409A pep. Our findings indicate the use of point-mutated Hsp65 molecules, such as the K409A protein and its corresponding peptide, that may minimize or delay the onset of SLE, representing a new approach to the treatment of autoimmune diseases.

**Introduction**

Heat shock proteins [Hsp] are among the most conserved molecules found in prokaryotes and eukaryotes. Intracellular Hsp molecules participate in fundamental cellular processes by acting as chaperones or chaperonins [1,2]. Under steady state conditions, Hsp molecules represent about 5% of the total intracellular proteins. Under stress conditions this rate may rise significantly [almost 5 times] [3]. The induction of Hsp expression is tightly controlled, as over-expression of this protein may persist or temporarily affect the intracellular homeostasis and may lead to cell death [4].

Despite its main function as a chaperone, the participation of the 60 kDa heat shock protein [Hsp60] in chronic-inflammatory processes, including autoimmune diseases, has been widely documented [3,5,6]. Heat shock proteins and their derived peptides have been shown to be involved in the pathogenesis of autoimmune diseases such as arthritis, diabetes, and intestinal inflammation as well as encephalomyelitis [reviewed in [6]]. It is believed that the Hsp molecules found in the extracellular compartment play a role in the evolution of autoimmune diseases [7,8]. In addition, inflammation can significantly increase endogenous Hsp levels, which affect the exposure of cryptic epitopes during antigen presentation and activates an immune response [9].

The fact that in pathophysiological conditions antibodies and T cells may react with self Hsp60 or bacterial Hsp65 suggests that these two proteins are capable of triggering cellular reactions in autoimmune diseases, because the similarity of the bacterial protein and the self antigen [6,10]. Moreover, increased levels of anti-Hsp60 and anti-Hsp65 antibodies are not restricted to pathological conditions, being also found in healthy individuals [11,12]. Response to proteins or any peptides should be a naturally occurring subliminal immune phenomenon that participates in the maintenance of neutralization and equilibrium in ordered states aimed to this class of endogenous molecules [13]. Based on the concept of molecular mimicry and on reports suggesting distinct physiological roles for self Hsp60 and bacterial Hsp65 molecules, it has been suggested that variable humoral responses to these proteins may correlate with the occurrence of chronic-degenerative and autoimmune processes [14].

Previously, it has been shown that by adding Hsp to any host an imbalance is observed in both the physiological and the immunological systems. Thus, it was hypothesized that the passive

---

**Citation:** Marengo EB, de Moraes LV, Melo RL, Balan A, Fernandes BL et al. (2011) A *Mycobacterium leprae* Hsp65 Mutant as a Candidate for Mitigating Lupus Aggravation in Mice. PLoS ONE 6(9): e24093. doi:10.1371/journal.pone.0024093

**Editor:** Pierre Bobè, Institut Jacques Monod, France

**Received:** April 1, 2011; **Accepted:** July 30, 2011; **Published:** September 22, 2011

**Copyright:** © 2011 Marengo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by funding from Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and National Council for Research and Development (CNPq-Brazil) – INCTTOX Program. EBM is the recipient of an FAPESP fellowship. LVM is the recipient of Fundação para Ciência e Tecnologia, Portugal. AB is supported by CNPq and ABTlus Associação Brasileira de Tecnologia de Luz Síncrona. DVT, LVR, and OAS are researchers at CNPq-Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: gbrazil@usp.br
administration of wild type [WT] M. leprae Hsp65 interferes with the body endogenous equilibrium by enhancing the entropy of the immunobiological system. Indeed, in a previous study we observed that the severity of Experimental Autoimmune Uveitis [EAU] [15] and the Systemic Lupus Erythematosus [SLE] [16] were increased in mice models that had the wild type M. leprae Hsp65 passively administered. In contrast, the administration of the K409A Hsp65, a point-mutated molecule [17], did not affect SLE evolution or survival; the combined administration of WT and K409A Hsp65 proteins showed that the K409A is able to inhibit but not reverse the effects of WT on F1 mice. These data suggest that Hsp65 has a central role in SLE progression, and that the K409A may mitigate and delay the development of SLE.

The point mutation of K409A M. leprae Hsp65 is located at the catalytic site. Thus, it was asked whether disease severity is an effect unrelated to the catalytic function of the WT molecule and whether this same region in either K409A or WT Hsp65 molecules play a role on the immunobiological effects associated to mice. To investigate this issue, it was synthesized two peptides that cover residues 352–371 of the M. leprae Hsp65 WT peptide [here called Leader pep] and its mutated form [here called K409A pep]. It was then observed how each of these peptides impacted the development and progression of SLE in murines. It was found that the immunomodulatory effects caused by each peptide were similar to that caused by their corresponding proteins and that the observed effect occurred regardless of the catalytic activity.

Results

Determination of primary structure, synthesis, and characterization of peptides

We have previously shown that administration of M. leprae Hsp65 in [NZBxNZW]F1 animals accelerated disease progression whereas the point-mutated K409A Hsp65 protein had opposite effects in the survival of F1 mice [16]. Since mutation was performed at the hypothetical catalytic site [17], we wanted to rule out the possibility that the enzymatic activity of the WT molecule was contributing to disease severity. For this, two synthetic peptides, corresponding to the 352–371 region of the WT and mutant Hsp65 molecules, named here as Leader pep and K409A pep respectively, were designed. These molecules comprise only part of the amino acid sequence of the putative catalytic site; in addition, the 352–371 Leader peptide cannot display any catalytic activity because it lacks the minimal structure necessary for an enzyme. Panel A in Figure 1 shows the analytical profile of the K409A pep purification after HPLC reverse-phase chromatography. The molecular mass of the K409A and Leader peptides corresponded to m/z 2,323.26 and m/z 2,380.54, respectively [Figure 1, panel B]. Panel C [Figure 1] shows the amino acid sequence of the Leader pep and K409A pep.

Immunomodulatory effects of synthetic peptides are similar to those of their respective proteins

[NZBxNZW]F1 mice of 45 day-old were inoculated with Leader or K409A pep and observed for 315 days [which correspond to the maximal survival time of the non-treated mice-control group] or for shorter periods if death occurred earlier than 315 days. Survival of the Leader pep-inoculated animals was significantly affected [p<0.01] with approximately 45% [9 out of 15] of mice dying at 53 days of age and showing a mean survival time [MST] of 58 days, as compared to non-treated mice [Figure 2, panel A - MST = 267±55]; 60% [3 out of 5] of the F1 mice inoculated with the K409A pep survived beyond the age of 315 days. Therefore, estimated survival time of these animals [263 day-old] was limited to the largest censored time, being significantly higher than the Leader pep-inoculated mice [p<0.05]. No significant differences were observed between K409A pep and control mice, but it is worth mentioning that no animal in the control group reached the age of 315 days. Thus, the inoculation with K409A pep may have increased the survival time of these mice. Moreover, peptide treatment generated similar effects on survival of F1 mice when compared to their respective WT and mutant Hsp65 proteins. There were no significant differences in response to DNA [titers approximately 7.5log2] and to Hsp65 IgG isotypes [titers approximately 4log2] in both experimental groups 7 days after the peptides were inoculated.

Treatment with mouse Hsp60 has no effect on SLE progression

It is hypothesized that the presence of the Hsp60 in the extracellular compartment can propagate the inflammatory response, thereby aggravating autoimmune diseases [6,18]. In order to evaluate if the mouse Hsp60 has a similar effect to that observed with Hsp65 of M. leprae in disease severity, the autologous Hsp60 protein was injected in F1 mice. Sequence alignment of the region corresponding to the synthetic peptide M. leprae Hsp65 and mouse Hsp60 proteins revealed 55% of sequence identity and the presence of seven amino acids highly conserved [Figure 2, panel B]. No difference in survival times was observed between these groups [Figure 2, panel C].

Anti-Hsp65 isotype production in HIII mice

To evaluate whether Hsp65 synthetic peptides – Leader and Mutant – were immunogenic, HIII mice were immunized and the anti-Hsp65 antibody levels at different time-points determined. Basal specific IgG1 antibody levels were observed in all experimental groups [Figure 3, panel A]. IgG2a antibody titers increased in both groups, starting with 4.5log2 on day 14 and reaching ~8log2 on day 25 post-immunization [Figure 3, panel B]. These data suggest that Hsp65 peptides are immunogenic even under non-inflammatory conditions, but not pathogenic since HIII mice did not develop any apparent illness. Notably, immunization of HIII mice with WT M. leprae Hsp65, emulsified in IFA, does not induce specific antibody titers [16].

The inoculation of K409A molecule and anti-K409A antibodies against Hsp65 mitigates SLE progression

In order to investigate if K409A molecules – protein and peptide forms – neutralize the effect of the wild type Hsp65 protein or of the Leader peptide, F1 female mice aging forty-five days received K409A pep or K409A protein and 7 days later were inoculated with the WT molecule or the Leader pep [K409A pep+WT or K409A+Leader pep groups, respectively]. Survival of the groups that received prior inoculation of mutant peptide or protein forms was significantly enhanced [K409A pep+WT group: 271±37 days, and K409A+Leader pep group: 289±54 days, p<0.001] when compared to groups previously administered with WT [WT+K409A group] or to those that received the Leader pep only. These latter groups showed an MST of 105±10 and 53±4 days, respectively [Figure 4, panels A and B]. The WT+K409A pep group was not included in this study because the K409A is able to inhibit but not reverse the effect of prior inoculation of Hsp65 WT protein on the [NZBxNZW]F1 mouse mortality [16].

To further investigate whether anti-K409A antibodies inhibit the effect of Leader peptide in SLE, F1 animals were inoculated with anti-K409A serum produced in HIII mice and adsorbed with the Leader pep or normal mouse serum [NMS]. Treatment with anti-
Figure 1. Characterization of $K^{409}A$ pep synthetic peptide. A) Purification of $K^{409}A$ pep synthetic peptide by reversed-phase chromatography. B) Mass spectrometry analysis of pure $K^{409}A$ pep; m/z 2,323.26. C) Amino acid sequence of Leader pep and $K^{409}A$ pep synthetic peptides.

Figure 2. Effect of the Leader pep and $K^{409}A$ pep peptides and autologous Hsp60 inoculation on SLE. A) Survival of [NZBxNZW]F$_1$ female mice ($n = 5$ to 15/group) inoculated with synthetic peptides at 45 day-old. Estimate was limited to the largest censored time [315 day-old]. *Data from [16]. MST = Mean survival time. *$p<0.05$; $K^{409}A$ pep versus Leader pep; **$p<0.01$: Leader pep versus control group; ***$p<0.001$: WT versus control group. Results are representative of 2 independent experiments. B) Amino acid alignment of *M. leprae* Hsp65 and mouse Hsp60. Amino acid homology colors: Identical: red; strongly similar: green; different: black. C) Survival of [NZBxNZW]F$_1$ 45-day-old female mice ($n = 5$ to 6) inoculated with mouse Hsp60 [●]; control group [▲]. Results are representative of 2 independent experiments.
Figure 3. Anti-Hsp65 antibody production in HIII mice. Time-course production of anti-Hsp65 IgG1 [A] and IgG2a [B] antibodies in HIII mice [n = 3 to 5/group] immunized with Leader pep or K409A pep. Antibody titers were evaluated at 7, 14, and 25 days after immunization with synthetic peptides. Results are representative of 2 independent experiments. Dashed lines represent basal levels. Data are expressed as means ± SD. doi:10.1371/journal.pone.0024093.g003

Figure 4. The neutralizing potential of previous inoculation of K409A molecule and anti-K409A antibodies on SLE suppression. A) Combined effect of K409A and WT in survival time. Forty-five-day-old female [NZBxNZW]F1 mice [n = 4 to 6/group] were inoculated with K409A pep or K409A, and after 7 days received WT rHsp65 [K409A pep+WT group: ■] or Leader pep [K409A+Leader pep group: ○]. *Data from [16]. *** p<0.001; K409A pep+WT and K409A+Leader pep versus WT+K409A group. B) Survival analysis of [NZBxNZW]F1 45-day-old mice [n = 4 to 7/group] inoculated with Leader pep [●]; Leader pep incubated with HIII normal mice sera [○]; or Leader pep incubated with HIII K409A-immunized mice [▲]. Leader pep group was the reference group for unpaired t-test analysis; ** p<0.01. Results are representative of 2 independent experiments. doi:10.1371/journal.pone.0024093.g004
K⁴⁰⁹ A adsorbed serum resulted in prolonged survival of mice previously inoculated with Leader pep, as compared to controls [Figure 4, panel B], suggesting that anti-K⁴⁰⁹ A antibodies neutralize the deleterious effect of the Leader pep.

Replacement of Lysine for Alanine at position 362 affects the electrostatic potential and interactions in M. leprae Hsp65

In order to better understand the effects of Hsp65 WT and K⁴⁰⁹ A protein- treatment in F₁ mice, structural models of both molecules were built. WT M. leprae Hsp65 and mutant were built based on the structural coordinates from M. tuberculosis Hsp65 [PDB code 1SJP_A] [19], which shows 79.7% of identity with the M. leprae Hsp65. The stereochemical quality of the models was evaluated with Procheck and the Ramachandran plot revealed 94.5% and 96% of residues in most favored regions for WT Hsp65 and mutant, respectively. No residues were found in generously allowed or disallowed regions in both models [data not shown]. For comparison, the mouse Hsp60 was also modeled using the structural coordinates of the chaperonin GroEL from E. coli [PDB code 1SX3] [20], which has 50% of amino acid sequence identity. Ramachandran plot for this model showed 94.8% of residues in most favored regions and none in generously or disallowed regions [data not shown]. All the models presented the three characteristic apical, intermediate, and equatorial domains found in E. coli Hsp60 [Figure 5, panel A, colored in yellow, magenta, and green, respectively] [21]. The peptide region is located in the apical domain [colored in orange and red], forming a “handle” that is very exposed and which does not interact with the ATP ligand-binding site in the equatorial domain [shown in red spheres]. In addition, based on the rigid model data, the substitution of Lysine 362 by Ala does not modify the alpha helix arrangement in the 352–371 region. The structural superposition of the three proteins revealed no significant differences, measured by the root mean square deviation [R.m.S.D.] for the a-carbon. Values varied from 0.4 Å [WT versus K⁴⁰⁹ A] to 1.1 Å [WT/K⁴⁰⁹ A versus mouse Hsp60] [Figure 5, inset table]. On the other hand, there are significant changes in the polar contacts and electrostatic potential of the peptide region, when compared among the three proteins. The position of the fragment covering residues 352 to 371 in the WT Hsp65 protein allows more inter alpha-helices M and Ë interactions [Figure 5, panel B and Table 1], than the same fragment in the Hsp65 K⁴⁰⁹ A and mouse Hsp60 [Figure 5, panels C and D, respectively, and Table 1]. According to this model, in the WT Hsp65, residues Y358, E361, K362, E365, and R366, [all of them located in the M helix in the 352–371 peptide region] compose eight contacts connecting helices Ë and L, including two contacts performed by the Lysine 362 [K362/NZ – D281/OD2, 2.8 Å and K362/NZ – Y358/OH, 2.9 Å; Table 1]. When Lysine is replaced by Alanine [K⁴⁰⁹ A mutant], only the R413, equivalent to the R366 in the WT Hsp65, has contacts with D336 of the L helix and E397 [Ê helix].

A slight increasing of the electrostatic potential is observed when the 352–371 fragment of both WT and mutant molecules are compared [Figure 5, panels B and C]. This may have some effect on the folding and structure of the M. leprae Hsp65. Curiously, although the mouse Hsp60 conserves the Lysine at the same position found in WT Hsp65, the number of interactions of the peptide region in this protein follows the profile of K⁴⁰⁹ A mutant Hsp and is similarly decreased [Figure 5, panel D and Table 1]. The amino acid hydropathicity and polarity of the peptide region in the three proteins was compared using Protscale server [22], according to [23] and [24], respectively. WT Hsp65 and K⁴⁰⁹ A showed similar profiles for polarity but an increased hydropathicity in Hsp65 K⁴⁰⁹ A, which is comparable to that calculated for mouse Hsp60, which shares only 55% of sequence identity with WT Hsp65, presented high polarity in the first eight residues of the 379–398 fragment [data not shown].

Distinct potential binding of the 352–371 amino acid regions of WT and K⁴⁰⁹ A proteins to MHC class I and II

Theoretical analysis evidenced that for the MHC class I only 1 out of 10 alleles of the H-2 molecule available for the RankPep recognizes the 352–371 region of WT and K⁴⁰⁹ A. The recognition ratio with the consensus sequences of each molecule of MHC class I was about 45% for both proteins [Figure 6 – panel A and B]. However, distinct class I molecules were predicted to bind to the 352–371 amino acid region of the Hsp65 wild-type and mutant molecules: the H-2d allele recognized the SDYDREKL peptide-epitope of WT [Figure 6 – panel A] and the H-2k allele recognized the ALQERLAKL of the mutant protein [Figure 6 – panel B]. For the MHC class II, 12 and 17 potential MHC peptide-binders to WT and K⁴⁰⁹ A molecules were respectively identified. There are 12 H-2 alleles and 49 HLA sub-alleles available at RankPep. While, the wild type and mutant proteins share these same alleles for class II, five additional HLA alleles that recognized the 352–371 region of K⁴⁰⁹ A exist [Figure 6 – panel D].

Discussion

Motivated by the opposite immunomodulatory effects of WT and K⁴⁰⁹ A Hsp65 on SLE, we analyzed the synthetic peptides corresponding to the region of the K⁴⁰⁹ A mutation in [NZBxNZW]F₁ mice, a model of spontaneous Systemic Lupus Erythematosus. Following our previously conceptual system based on the addition of Hsp to imbalance the endogenous equilibrium of the immunobiological system [16], the Leader and K⁴⁰⁹ A peptides were passively administered to these F₁ mice. Here the primary sequence of synthetic peptides derived from M. leprae Hsp65 and their effects in this model are presented. The present data showed that, in general, the action of these synthetic peptides resembled that of their respective proteins, indicating that the residues 352–371 of both M. leprae Hsp65 and of the mutated form K⁴⁰⁹ A are the ones responsible for the effects on mice survival. This rules out the hypothesis that the immunomodulatory effect previously observed [16] was associated with a catalytic activity of the M. leprae Hsp65. Furthermore, the effect of each peptide was comparable to that observed in its corresponding proteins. Not only that but this effect was also amplified. In other words, there is a reduction in the survival time of mice injected with the Leader pep, and a tendency for increased survival time with K⁴⁰⁹ A pep inoculation, as compared to the survival times observed with the two corresponding proteins. Although there were no significant differences in survival times between K⁴⁰⁹ A pep and the control group, a lower standard deviation in K⁴⁰⁹ A pep-inoculated animals was observed, suggesting that this peptide could increase the survival of animals that would otherwise have an early death, possibly being the ones with more severe disease. Similar observations have been made previously in lupus animals inoculated with the K⁴⁰⁹ A Hsp65 protein [16].

Because the administration of K⁴⁰⁹ A protein as well as K⁴⁰⁹ A pep had no effect on mortality of [NZBxNZW]F₁ and the K⁴⁰⁹ A protein presents higher immunogenicity than the WT Hsp65 [16], the effects of the co-administration of K⁴⁰⁹ A+Leader pep or K⁴⁰⁹ A pep+WT on the survival of F₁ animals were evaluated. The survival times of K⁴⁰⁹ A+Leader pep and K⁴⁰⁹ A pep+WT animals were significantly higher when compared to Leader pep or WT-
inoculated animals. These results indicate that the K409A protein and its corresponding synthetic peptide are able to inhibit the deleterious effect of the Leader pep or WT on the mortality of the [NZBxNZW]F1 mouse. Indeed, the transfer of the anti-K409A serum produced in H3II mice and adsorbed with the Leader pep reinforces the mitigating effects of K409A forms in SLE. Altogether, these data indicate the neutralizing potential of prior inoculation of K409A molecule, both protein and its peptide, and anti-K409A antibodies against Hsp65, and possibly against autologous Hsp60. Further protein–protein interaction studies will expand our knowledge on the potential therapeutic application of K409A forms on lupus disease, and possibly on other chronic degenerative autoimmune processes.

Despite the various pro-inflammatory properties described for Hsp60 family members [25,26,27,28], other reports support an immune regulatory role for self Hsp60 [29,30,31,32,33]. Here, the administration of autologous Hsp60 protein did not change survival of F1 animals. Thus, it is possible that in this model the recombinant Hsp60 does not activate immune cells; otherwise the molecule would be recognized as a self-antigen. However, it is possible that administration of higher doses of autologous Hsp60 [2.5 mg] interferes with lupus progression.

The sequence alignment analysis of 352–371 amino acids of M. leprae Hsp65 and the corresponding 379–398 of mouse Hsp60 shows 55% of identity and an additional of 30% of strongly conserved amino acids. The literature shows that the amino acid

**Table 1.** Polar contacts identified in the three models built for WT Hsp65, Hsp65 K409A, and mouse Hsp60.

| WT Hsp65 | Hsp65 K409A | mouse Hsp60 |
|----------|-------------|-------------|
| residue 1 | residue 2 | distance (Å) | residue 1 | residue 2 | distance (Å) | residue 1 | residue 2 | distance (Å) |
| R343/NZ  | D289/OD1   | 2.7         | E397/OE1 | R413/NH1 | 2.7         | R393/NH1  | D315/OD2 | 2.8         |
| E350/OE2  | R366/NH2   | 2.8         | D336/OD2 | R413/NH2 | 2.7         | K389/NZ  | Y385/OH  | 3.1         |
| E350/OE2  | R366/NH1   | 2.7         | R390/NH1 | Q335/OE1 | 2.8         |
| R282/NH1 | E365/OE2   | 2.8         |             |             |             |             |             |             |
| R282/NH2 | E365/OE2   | 2.8         |             |             |             |             |             |             |
| R282/NH1 | E361/OE2   | 3.0         |             |             |             |             |             |             |
| K362/NZ  | D281/OD2   | 2.8         |             |             |             |             |             |             |
| K362/NZ  | Y358/OH    | 2.9         |             |             |             |             |             |             |

The region showed refers to the residues 352 to 371, according to the number of residues of the WT Hsp65 protein. Contacts in bold are those performed by K362 in WT Hsp65 and K389 in mouse Hsp60.

doi:10.1371/journal.pone.0024093.t001

**Figure 5.** Structural modeling of *M. leprae* WT and K409A Hsp65 and mouse Hsp60. A) Superposition of the WT and K409A *M. leprae* Hsp65 overall structures showing the three characteristic domains: apical [yellow], intermediate [red], and equatorial [green], with the ADP evidenced in spheres. The peptide region [352 to 371 residues in WT Hsp65] is evidenced in orange and regions with high B-factor described by [21] are shown in red. The inset table shows the results of the structural alignment of the proteins. B, C, and D) Main differences in the polar contacts performed by the peptide region and that affect the electrostatic potential in the WT Hsp65, Hsp65 K409A, and mouse Hsp60 proteins, respectively. Red color shows negative and blue positive charges.

doi:10.1371/journal.pone.0024093.g005
differences between mouse Hsp60 and bacterial Hsp65 include the less conserved regions of these molecules, which are recognized by vertebrate T cells [34]. Taken together, these observations reinforce the idea of a higher immunogenic property of *M. leprae* Hsp65 as compared to that of autologous Hsp60 in disease aggravation. They also suggest a lack of cross-reactivity of conserved epitopes corresponding to the synthetic peptide between mycobacterial Hsp65 and mouse Hsp60. This finding supports the view that the structural similarity of the epitopes, based on the anchor residues, is more important than the homology of the primary sequence.

Several crystal structures of GroEL – *E. coli* Hsp60 chaperonin 1 [cpn60-1] and from other organisms are available and two of them show GroEL in its 14-meric structure [21,35]. For the mycobacterial Hsp65, the crystal structure of Hsp65 *M. tuberculosis* reveals its dimeric state and suggests that the concentration of Hsp65 found in the extracellular milieu is extremely low for oligomer formation [19,36]. Also, the differences in the primary sequence of the two chaperonins [cpn60] homologs of *M. leprae* – cpn60-1 [Hsp60] and cpn60-2 [Hsp65] – may contribute to the divergent structural and functional properties observed in the Hsp60 family members.

Here, the tertiary structure of *M. leprae* Hsp65 and its mutant K409A were based on templates of crystal monomer structure of the *M. tuberculosis* Hsp65 [PDB code 1SJP] [19] and of the chaperonin complex from *Thermus thermophilus* [PDB code 1WE3] [37]. No significant changes in the tertiary structure of both proteins, including the predicted alpha-helix where the mutated Lysine K409A is located, were observed. However, although the WT and mutant Hsp65 are expressed as rigid structures based on a model that fixes the positions of amino acids, replacing Lysine 362 by Alanine affects the electrostatic potential of the region and the potential interactions performed by Lysine 362 and the residues located around it. Importantly, the mutation at the 352–371 region probably does not affect the molecular stability, regardless whether it is in its heptamer or monomer structures, because this region is distantly located from the ATP binding site. In addition, the number of interactions observed at this site of the WT Hsp65 is highly decreased when compared to mouse Hsp60 and Hsp65 K409A; both these proteins showed a similar hydrophobic profile for the equivalent 352–371 region of Hsp65. These features could be related to the lack of effect and enhancement of survival of F1 mice when they were inoculated with autologous Hsp60 or K409A pep, respectively. As mentioned, because the models are shown as rigid structures, it is possible that the differences in the peptide region affect the positions and interactions between *M* and *J* helices. Interestingly, one of the regions evidenced by [21] that shows the high B-factor of the predicted protein structures, and is located exactly in the most exposed area of the peptide region [Figure 5, panel A], is related to a loss of interactions between the helices that are associated to the higher mobility of the apical region. This could lead to drastic effects on the 352–371 peptide region and protein of the K409A Hsp65 structure and could change the interaction with other molecules.

The structural model shows that the 352–371 region of the Hsp65 is exposed, and it is possible that it can be recognized by the immune system. Our current data from immunization of HIII mice with the Leader or K409A peptides show that, in general, the synthetic peptides seem to be more immunogenic when compared to their corresponding proteins [16], especially for the wild type protein form. A group of small peptides and a 20.4 kDa fragment of the C-terminal portion from Hsp65, commonly found on the cell wall of *M. leprae*, are in the cytosol of the bacillus [38]. *In vitro* studies also show a potential autolysis of *M. leprae* Hsp65 by releasing portions of its N- and C-terminal regions, suggesting that the antigen presentation occurs independently of the proteasoma [39]. The process of chaperone/
chaperonin autolysis has also been described for other Hsp families and it is believed that self-degradation is a modulation process [39]. Therefore, the inflammation observed in chronic inflammatory processes, including autoimmune diseases, may change the conformation, the antigen processing, or self-degradation of the Hsp65. This hypothesis is supported by a recent paper from [40]. Inflammation may also expose or more efficiently release new determinants/epitopes, or certain epitopes such as the cryptic ones [16], and possibly the region that comprises the 352–371 peptide. Discrimination between the pathological and regulatory Hsp60 actions in autoimmunity is still unclear, even whether the regions of the Hsp60 may determine their opposing immunological function. However, some reports suggest that different regions of the Hsp60 molecules induce distinct immune response; proliferative response induced by N-terminal and intermediate Hsp60 peptides, which also induced IFN-γ production; also, the IL-4 production was induced by the intermediate and C-terminal regions [30]. It was reported that a C-terminal region of Hsp60 [354–366 amino acid] was involved in LPS binding and innate immune activation [41]. On the other hand, the p277 peptide from 437–460 amino acids of the human Hsp60 molecule presented immunoregulatory effect in non-obese diabetic NOD mice, by inducing IL-4 and IL-10 production [42,43].

Although there were no significant differences in the production of anti-DNA and anti-Hsp65 IgG isotypes it is possible that these antibodies differ in their binding affinity, leading to distinctive potential pathogenic involvements. In the present model, a preliminary analysis indicates that in mice receiving WT or K<sup>409A</sup> proteins, the avidity was ten times higher than their respective peptides and controls at 30-day-old mice [data not shown]. The exact pathophysiology mechanism behind the phenomenon evoked by the K<sup>409A</sup> has not been identified. Preliminary results showed that the K<sup>409A</sup>-inoculated lupus mice presented lower number of lymphocytes in spleen when compared to WT mice group and controls and that this effect is not mediated by direct induction of apoptosis evaluated in <i>vitro</i> at 2 and 24 hours. Furthermore, total spleen cells treated with K<sup>409A</sup> protein or its peptide indicate that these mutant forms did not affect <i>vitro</i> cell proliferation assay. Thus, it can be suggested that modulation rather than activation is what occurs in the immune system. In addition, no differences in frequency of <i>ex vivo</i> CD<sup>4+</sup>CD<sup>25+</sup> and CD<sup>4+</sup>CD<sup>122+</sup> populations were observed. Neither difference was observed in IL-2 cytokine production in splenic cells in WT and mutant groups when compared to controls. Also, no differences in splenic IL-10 levels were observed [unpublished data]. It is possible that, at least in part, the immunomodulatory effect of the K<sup>409A</sup> protein/peptide is explained by a balanced production of IgG1 and IgG2a anti-DNA along the life and high levels of humoral IFN-γ in this experimental group when compared to WT and control groups [16]. In a systemic and multifactorial chronic disease such as SLE, it must be considered that there is not a unique explanation and assertion, since competing and overlapping mechanisms occur in different compartments and at the same time.

The discordant results obtained <i>vitro</i> with WT and K<sup>409A</sup> forms raise some questions, considering that the protein and the peptide are point-mutated molecules. The analyses of RANKPEP prediction of peptide-epitope of WT and K<sup>409A</sup> Hsp63 were relatively distinct in their potential to bind to MHC molecules. Therefore, it can be hypothesized that the MHC Hsp65-binding potential is one of the features responsible, at least in part, for the effects that Hsp65 causes in the survival of F<sub>1</sub> mice. Because the concomitant administration of the K<sup>409A</sup> pep and Leader pep in lupus mice had a predominant effect of the mutant peptide, we assume that they compete for the same target on molecular and cellular levels, such as antigen presenting cells and MHC molecules. This hypothesis deserves further investigation.

As shown in our studies, a single base change in the DNA can have remarkable effects, such as those artificial changed molecules observed for the altered peptide ligands [APL]. There are reports in the literature of natural variants or mutations of <i>M. leprae</i> Hsp65 [44]. Additionally, amplification of some regions of the <i>M. leprae</i> Hsp65 may be used for a differential diagnosis of leprosy [45]. Nevertheless, the molecular and cellular mechanisms caused by these variations in the <i>M. leprae</i> Hsp65 in infected individuals remain unknown.

Our findings suggest that the use of point-mutated molecules, such as the K<sup>409A</sup> protein and its corresponding peptide, may minimize or delay the onset of SLE, representing a new possibility of treatment for this and other autoimmune diseases.

Evolutionarily, adaptations towards the functional aspects of the proteins might have been initially predominantly and, along eras, associated to the progressive organism complexity, as structural diversities were fixed. Distinct functions, binding motifs, and molecular interactions are reflected in conserved families, such as those of the immunoglobulins or of the heat shock proteins. Thus, the molecular evolution would be defined by the capacity of the combination potential between molecules, their affinity, and molecular conformation in the <i>late</i> sense. Relative to energy dissipation, it can be assumed that during the evolutionary process, the best intermolecular adjustment determines species survival. The molecular relationships and the cellular interactions can be understood as actions defined for balance and sequential reactions. The dynamics of the complex network that delineates the immune system, and also the complex toxicity processes, can be included in the contexts of imbalance of dissipative structures and ordered disorganization, which are guided by causal and extemporal sequences. It must take into account that the perception of the significance of the concept of self/non-self is limited by possibilities of detection or not, of binding to or neo-exposition of pre-existing molecules. To the qualitative network emergence must be adjoined the extremely variable and complex quantitative and pleitropic expression of responsiveness. For most of the physiological processes that are cumulative and irreversible [mainly those related to the immune system] it is possible that even though irregularities, a variety of subliminal and undetected pathological processes could be initiating. Based on these and our previous data, Hsp could be understood as toxins. Immunities or toxins, behaving as a broken mirror in which similarities or contrasts acquire variable structures and expressions along the individual life, give surety to species survival.

Materials and Methods

Animals

Mice were caged and handled under ethical conditions, according to international rules of animal care specified in the International Animal Welfare Recommendations [46]. New Zealand Black [NZB] female and New Zealand White [NZW] male mice were obtained from the animal facilities of the University of São Paulo, Brazil and from the Gonçalo Moniz Research Center, Salvador, Bahia, Brazil. The genetically selected high responder mice [H<sub>HI</sub> line] were obtained from the Immunogenetics Laboratory of Instituto Butantan, São Paulo, Brazil. Parental lines were mated in our laboratory to produce [NZBxNZW]F<sub>1</sub> hybrids. After weaning, F<sub>1</sub> mice were housed in groups of four to six animals in plastic cages filled with hardwood
bedding, and were provided with water and rodent feed *ad libitum*. The animals were kept in a room with controlled lighting [12-h light/dark cycle], pressure, humidity, and temperature [24°C]. All the procedures were approved by the Institutional Animal Care Committee at Butantan Institute [CEUAIB # 196/05].

**Peptide synthesis**

Leader pep [ENSDSDYDREKLRQLERLAKLA] of *M. leprae* Hsp65 and K<sup>409</sup>A pep [ENSDSDYDREKLRQLERLAKLA] of the mutated form K<sup>409</sup>A, both covering residues 352–371, were synthesized using the Fmoc-[N-(9-fluorenylmethoxycarbonyl)] procedure [47] in a Shimadzu PSSM-8 peptide synthesizer [Shimadzu, Tokyo, Japan]. The Fmoc-amino acids were purchased from Novabiochem [Nottingham, UK]. The synthetic peptides were purified by preparative reversed-phase chromatography [reversed-phase HPLC], and the purity and identity of the peptides were confirmed by matrix-assisted laser desorption ionization time-of-flight [MALDI-TOF] mass spectrometry on an Agilent MALDI-TOF/Pro instrument [Amersham Biosciences, Buckinghamshire, UK] and by analytical reversed-phase high performance liquid chromatography [HPLC] [Shimadzu Inc., Tokyo, Japan].

**Expression of the recombinant *M. leprae* Hsp65 in Escherichia coli**

Expression and purification of the recombinants *M. leprae* WT and K<sup>409</sup>A Hsp65 was done as described in [16].

**Animal treatment**

Forty-five-day-old female [NZBxNZW]F<sub>1</sub> mice were intraperitoneally injection i.p.) inoculated with a single dose of 2.5 µg of Leader pep or K<sup>409</sup>A pep in 0.2 ml of phosphate buffer saline pH 7.4 [PBS]. An additional group of animals was inoculated with 2.5 µg of mouse Hsp60 [Stressgen, ESP-741D] in 0.2 ml of PBS. The number of animals varied between 3 and 15 per group and control mice received 0.2 ml of PBS. Peptide-inoculated and control mice were periodically bled and the individual serum samples stored at −20°C until titration by ELISA of the anti-DNA and anti-Hsp65 antibodies. Animals were evaluated until 315 days of age or until their death. Mice were periodically examined for clinical signs including development of ascites, lethargy, and anorexia, and death.

**Anti-Hsp65 antibody production in High responder mice**

Three- to four-month-old H<sub>III</sub> mice were immunized subcutaneously with 10 µg of WT rHsp65, K<sup>409</sup>A, Leader pep, or K<sup>409</sup>A pep emulsified in incomplete Freund's adjuvant [IFA] [v/v] in a final volume of 200 µL. These high responder mice were genetically selected according to high responsiveness and expressed no epitope nor isotype restrictions [48,49]. For the recombinant Hsp63 proteins, after approximately 15 days of immunization [primary response], animals received a subcutaneous booster of 10 µg of the respective recombinant proteins emulsified in IFA [v/v] in a final volume of 200 µL. Mice were periodically bled by retro-orbital venous plexus and the samples collected were kept at −20°C for further analysis of individual primary and secondary responses.

**In vitro and in vivo sera assays**

The in vitro and in vivo neutralizing sera assays were carried out as follows: 2.5 µg of Leader pep were incubated for 30 minutes at 37°C with serum anti-K<sup>409</sup>A produced in H<sub>III</sub> mice [as described above] or H<sub>III</sub> normal mice serum [NMS] at 1:4 dilution. Mixtures were centrifuged at 14000 rpm for 10 minutes at 4°C, and the supernatants were collected and inoculated in [NZBxNZW]F<sub>1</sub> female mice [n = 4–7/group] with 45 days of age by the intraperitoneal route. As control, F<sub>1</sub> mice were inoculated with 2.5 µg of Leader pep. Clinical signs, including ascses development, lethargy, and anorexia, as well as the mean survival time were evaluated.

**Combined administration of recombinant Hsp65 and synthetic peptides**

Forty-five-day-old female [NZBxNZW]F<sub>1</sub> mice were inoculated i.p. with a single dose of 2.5 µg of K<sup>409</sup>A pep or K<sup>409</sup>A protein in 0.2 ml of PBS. Seven days later, animals received 2.5 µg of WT rHsp63 or Leader pep, i.p. Mice were periodically bled; individual serum sample titration and clinical signs were evaluated as described above.

**Titration of anti-DNA and anti-Hsp65 antibodies**

Specific IgG1 and IgG2a isotypes were detected with indirect ELISA as described in [16].

**Molecular modelling of the tridimensional structures of *M. leprae* Hsp65 and mouse Hsp60**

The structural models of *M. leprae* WT and K<sup>409</sup>A mutant Hsp65 and mouse Hsp60 were generated using the Modeller 9v2 program [50], driven by satisfaction of spatial restraints, using the protein sequences P09239 and P03038, respectively. Search for best models were performed using FUGUE [51] and PSI-Blast against Protein Data Bank as a search set. The mouse Hsp60 tridimensional model was generated based on the atomic coordinates of the *Escherichia coli* chaperonin GroEL [PDB code 1SX3] [20], which shares 50% of sequence identity. For building of *M. leprae* Hsp65 models, two proteins were used. The atomic coordinates from the chaperonin complex from *Thermus thermophilus*, chain A [37] were used for modelling of N and C termini [PDB code 1W35, residues 3 to 70 and 510 to 529, respectively] and the structural coordinates of the Hsp65 from *M. tuberculosis* [PDB code 1JSF, residues 60 to 514] [19]. The best models were chosen according to the Modeller objective function and stereo chemical analyses using Procheck [32]. Angle distortions and rotamers were corrected using COOT [53]. Secondary structure matching [SSM] superposition of the models was obtained according to [54]. All the figures and the electrostatic potential calculation were obtained with “The PyMOL Molecular Graphics System” [55].

**Alignment of Hsp60 amino acid sequences**

The primary structure analysis of the mouse Hsp60 and *Mycobacterium leprae* Hsp65 was performed using the Clustal W multiple alignment website [http://www.phil.ibe.cnr.it], supplied with sequences deposited in the SWISS-PROT/TrEMBL database [http://expasy.org/sprot], access number: *M. leprae* Hsp65: P09239; mouse Hsp60: P63038.

**Major Histocompatibility Complex (MHC) class I and II epitope binding prediction**

The potential binding of the 352–371 amino acid regions of WT and K<sup>409</sup>A proteins to MHC class I and II was analyzed using the RankPep tool. Theoretical recognition ratio in the consensus sequences of each molecule of MHC class I and II and the number of the molecules that recognize the peptides were calculated for both proteins.

**Statistical analysis**

Antibody production data are expressed as the mean [X] ± standard deviation [SD] and compared by unpaired *t*-test.
Survival time was analyzed by Kaplan-Meier curves and log-rank test. Statistical significance was set at p<0.05.

Acknowledgments

We are grateful to Dr. Vitor Maflili [Goncålho Moniz Research Center, Salvador, Bahia, Brazil] for donation of the NZB and NZW parental mice. We would like to thank the assistance of Marcia Triumfol Eliblink of Publicize with the English review, Ângela Tavares Paes and Elivane da Silva Victor [Centro de Pesquisa Clínica – Hospital Israelita Albert Einstein] for assistance with statistical analyses.

Author Contributions

Conceived and designed the experiments: EBM LVM LVR OAS. Performed the experiments: EBM AB RLM OAS. Analyzed the data: EBM LVM AB INT LVR OAS. Contributed reagents/materials/analysis tools: RLM LVR OAS. Wrote the paper: EBM LVM AB BLF LVR OAS.

References

1. Ellis J (1987) Proteins as molecular chaperones. Nature 328: 378–379.
2. Georgopoulos C (1992) The emergence of the chaperone machines. Trends Biochem Sci 17: 295–299.
3. Zieg U, Kaufmann SH (1999) Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12: 19–39.
4. Pockley AG (2003) Heat shock proteins as regulators of the immune response. Lancet 362: 469–476.

Perschinka H, Mayr M, Millington G, Mayerl C, van der Zee R, et al. (2003) Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in rheasclerosis. Arterioscler Thromb Vasc Biol 23: 1060–1065.

6. Rajah R, Moudgil KD (2009) Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev 8: 290–293.
7. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12: 1539–1546.
8. Saito K, Dai Y, Ohnaka K (2005) Enhanced expression of heat shock proteins in gradually dying cells and their release from necrotically dead cells. Exp Cell Res 310: 229–238.
9. Durai M, Kim HR, Moudgil KD (2004) The regulatory C-terminal determinants within mycobacterial heat shock protein 65 are cryptic and cross-reactive with the dominant self-homologs: implications for the pathogenesis of autoimmune arthritis. J Immunol 173: 101–108.
10. Dudani AK, Gupta RS (1989) Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Infect Immun 57: 2786–2793.
11. Pockley AG, Bolmer J, Hanks BM, Wright BH (1999) Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones 4: 29–35.
12. Xu Q, Schett G, Perschinka H, Mayr M, Egger G, et al. (2000) Serum soluble heat shock protein 60 is elevated in patients with spondyloarthritis in a general population. Circulation 102: 14–20.
13. Tsuruta LR, Hayashi MA, Konno K, Tambourgi DV, Assakura MT, et al. (2006) A natural carrier effect and the generation of specific antibodies to biologically active peptides. Anal Biochem 353: 174–180.
14. Xiao Q, Mandel K, Schett G, Mayr M, Wick G, et al. (2003) Association of serum soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study. Stroke 34: 2571–2576.
15. Marengo EB, Comandrogo AV, Peron JP, de Moraes LV, Porto FC, et al. (2009) Administration of Mycobacterium leprae hsp65 aggravates experimental autoimmune uveitis in mice. PLos One 4: e7912.
16. Marengo EB, de Moraes LV, Faria M, Fernandes BL, Carvalho LV, et al. (2008) Mycobacterium leprae hsp65 displays proteolytic activity. Immunity 29: 412–418.
17. Portaro FC, Hayashi MA, De Arauz LJ, Palma MS, Assakura MT, et al. (2002) The Mycobacterium leprae hsp65 proteolytic activity is catalytically related to the HslVU protease. Biochemistry 41: 7400–7406.
18. Santerre J, Adami B, Honore S, Lavoie A, Beaudoin P, et al. (2007) Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 37: 224–232.
19. Zanin-Zhovit A, Bruck R, Tal G, Oren S, Aref H, et al. (2005) Heat shock protein 60 inhibits Th1-mediated hepatitis model via innate regulation of Th1/Th2 transcription factors and cytokines. J Immunol 174: 3277–3286.
20. Prehsakza Z, Diba J, Lagois G, Kiss E, Varga L, et al. (1999) Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability. Int Immunol 11: 1553–1567.
21. Xu Z, Horwich AL, Sigler PB (1997) The crystal structure of the asymmetric GroEL-GroES(ADP7) chaperonin complex. Nature 388: 741–750.
22. Qamra R, Srivinas V, Mande SC (2004) Mycobacterium tuberculosis GroEL homologues unusually exist as 60 kDa Triton X-100 soluble and retain the ability to suppress aggregation of substrate proteins. J Mol Biol 342: 605–617.
23. Shimamura T, Koike-Takeshita A, Yokoyama K, Masui R, Murai N, et al. (2004) Crystal structure of the native chaperonin complex from Thermus thermophilus revealed unexpected asymmetry at the cis-cavity. Structure 12: 1471–1480.
24. Marques MA, Chitale S, Brennan PJ, Pessolani MC (1998) Mapping and identification of the major cell wall-associated components of Mycobacterium tuberculosis. Infect Immun 66: 9245–9252.
25. Mitchell HK, Petersen NS, Buzin CH (1985) Self-degradation of heat shock proteins. Proc Natl Acad Sci U S A 82: 4969–4973.
26. Parada CA, Porto F, Marengo EB, Kitzke CF, Vicente EJ, et al. Autolytic Mycobacterium leprae hsp65 fragments may act as biological markers for autoimmune diseases. Microb Pathog. 2003 Dec;35(2):172–179.
27. Habich C, Kempe K, Gonzalez JJ, Lallercrap M, Gaston H, et al. (2006) Heat shock protein 60: identification of specific epitopes for binding to primary macrophages. FEBS Lett 580: 113–120.
28. Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343: 704–706.
29. Elias D, Meilin A, Bouthillier Y, Mevel JC, et al. (1985) Modulation of anti-insulin antibody response to a recombinant human insulin B chain fragment in diabetic rats: possible therapeutic potential. J Clin Invest 75: 301–307.
30. Luna E, Postel E, Caldas C, Mundel LR, AB LVM AB DVT LVR OAS. Contributed reagents/materials/analysis tools: RLM LVR OAS. Wrote the paper: EBM LVM AB BLF LVR OAS.
to the polygenic control of antibody responsiveness in mice. Immunogenetics 22: 131–139.
50. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779–815.
51. Shi J, Blundell TL, Mizuguchi K (2001) FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol 310: 243–257.
52. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK - a program to check the stereochemical quality of protein structures. J Appl Crystal 26: 283–291.
53. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
54. Krissinel E, Henrick K (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60: 2256–2260.
55. DeLano WL (1998–2003) The PyMOL Molecular Graphich System. DeLano Scientific LLC San Carlos, California, USA.